Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Actuate Therapeutics IncNASDAQ: ACTU
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $3.14M fell 0.1% year over year, behind the +39.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +47.3% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +88.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.14M+22.8% QoQ
- Last fiscal yearDec 2025
- $12.2M+88.2% YoY
- LTMMar 2026
- $12.2M+39.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.1% | -100.0% | -99.9 pp |
| 1 year | +88.2% | -100.0% | -188.2 pp |
| 3-year CAGR | +47.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.2M USD
- Year-over-year change
- +88.2%
- 3-year CAGR
- +47.3%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.2M | +88.2% |
| FY2024 | 2024-12-31 | 6.48M | +98.6% |
| FY2023 | 2023-12-31 | 3.27M | -14.5% |
| FY2022 | 2022-12-31 | 3.82M | — |
Selling, General & Admin vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.9% is the 2nd highest of 9, against a peer median of -11.8%.
- Over three fiscal years its annual growth of +47.3% compares with a peer median of +0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $51.12M USD | +107.0% | +36.0% | — | |
| LTM Mar 2026 | $47.37M USD | -20.9% | -4.0% | 257.2% | |
| LTM Mar 2026 | $35.34M USD | -27.5% | -17.7% | 3080.9% | |
| LTM Mar 2026 | $25.06M USD | -19.7% | +4.0% | — | |
| LTM Mar 2026 | $22.56M USD | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $19.24M USD | -21.8% | -16.6% | 35.1% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $12.2M USD | +39.9% | +47.3% | — |
| Peer median (excluding ACTU) | — | -11.8% | +0.0% | 257.2% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 16.39M | 21.71M | 18.68M | 10.29M |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M |
| Depreciation & Amortization | 63.61K | 272.85K | 2.14M | 0 |
| EBITDA | (20.08M) | (24.43M) | (25.16M) | (22.21M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (20.21M) | (24.97M) | (25.16M) | (22.5M) |
| Operating Margin | — | — | — | — |
| Interest Income | 27.03K | 352.67K | 222.29K | 287.71K |
| Interest Expense | 16.2K | 43.64K | (18.72K) | 20.25K |
| Other Income / Expenses | 47.41K | 229.21K | (2.12M) | 267.46K |
| Income Before Tax | (20.16M) | (24.74M) | (27.28M) | (22.23M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 800 | 0 |
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (1.34) | (1.65) | (3.26) | (1.06) |
| EPS (Diluted) | (1.34) | (1.65) | (3.26) | (1.06) |
| Weighted Avg Shares | 15.03M | 15.03M | 19.51M | 21.02M |
| Weighted Avg Shares (Diluted) | 15.03M | 15.03M | 19.51M | 21.02M |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.